Artemis II’s AVATAR and a Sungrazing Comet - Planetary Radio
Why It Matters
Avatar will provide the first personalized biological data from deep‑space travel, shaping health safeguards for future crewed missions, while the comet’s close solar pass offers a rare scientific observation opportunity.
Key Takeaways
- •Artemis II will launch personalized organ‑chip “Avatar” experiments to study deep space.
- •Bone‑marrow chips mimic astronaut immune response under radiation.
- •Chips are perfused by Space Tango’s autonomous system aboard Orion.
- •Data will enable individualized medical countermeasures for future crew.
- •A newly discovered sungrazing comet will pass 162,000 km from Sun.
Summary
The episode of Planetary Radio focuses on NASA’s Artemis II mission, highlighting the Avatar organ‑chip experiment and the imminent passage of a sungrazing comet. It introduces Lisa Carnell, director of NASA’s Biological and Physical Sciences Division, and astronomer Alan Mori discussing the comet.
Avatar consists of bone‑marrow organ chips derived from each astronaut’s blood via apheresis, placed in a USB‑size cartridge that will travel with the crew on the ten‑day lunar flyby. The chips experience the same microgravity and deep‑space radiation, allowing direct comparison with Earth‑based controls. Space Tango provides an autonomous perfusion system that maintains temperature, fluid flow, and power for the duration.
Carnell emphasized the experiment’s novelty, noting “this is the first time organ chips have flown beyond the Van Allen belts matched to individual crew members.” She described how bone‑marrow sensitivity reveals early immune changes, and Mori warned that the comet’s perihelion at 162,000 km could test observational capabilities if it survives.
Successful data will inform personalized countermeasures for radiation and immune suppression, a prerequisite for longer missions to Mars. Moreover, monitoring the comet offers insights into solar‑proximity dynamics, enriching both planetary science and public engagement.
Comments
Want to join the conversation?
Loading comments...